Boothbay Fund Management LLC Invests $12.80 Million in Cullinan Therapeutics, Inc. $CGEM

Posted by Brenda Bartman on Jun 18th, 2026

Boothbay Fund Management LLC purchased a new position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 1,237,043 shares of the company’s stock, valued at approximately $12,803,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Lynx1 Capital Management LP boosted its stake in shares of Cullinan Therapeutics by 31.0% during the 3rd quarter. Lynx1 Capital Management LP now owns 5,766,090 shares of the company’s stock worth $34,193,000 after acquiring an additional 1,365,248 shares during the last quarter. Blue Owl Capital Holdings LP boosted its stake in shares of Cullinan Therapeutics by 5.2% during the 3rd quarter. Blue Owl Capital Holdings LP now owns 2,510,972 shares of the company’s stock worth $14,890,000 after acquiring an additional 125,000 shares during the last quarter. State Street Corp boosted its stake in shares of Cullinan Therapeutics by 31.0% during the 4th quarter. State Street Corp now owns 2,197,338 shares of the company’s stock worth $22,742,000 after acquiring an additional 520,024 shares during the last quarter. Affinity Asset Advisors LLC boosted its stake in shares of Cullinan Therapeutics by 632.4% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,932,106 shares of the company’s stock worth $19,997,000 after acquiring an additional 1,668,289 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Cullinan Therapeutics by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,302,262 shares of the company’s stock valued at $13,481,000 after purchasing an additional 6,942 shares during the period. Hedge funds and other institutional investors own 86.31% of the company’s stock.

Cullinan Therapeutics Price Performance

Shares of CGEM stock opened at $14.44 on Thursday. The company has a market capitalization of $887.48 million, a price-to-earnings ratio of -4.30 and a beta of -0.01. The company’s fifty day moving average price is $14.42 and its 200-day moving average price is $13.05. Cullinan Therapeutics, Inc. has a one year low of $5.68 and a one year high of $16.74.

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.09. Equities research analysts expect that Cullinan Therapeutics, Inc. will post -3.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CGEM has been the topic of several recent analyst reports. Zacks Research downgraded shares of Cullinan Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 19th. Wedbush restated an “outperform” rating and set a $37.00 price objective on shares of Cullinan Therapeutics in a research report on Thursday, June 11th. Wall Street Zen upgraded shares of Cullinan Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday. Weiss Ratings restated a “sell (d-)” rating on shares of Cullinan Therapeutics in a research report on Friday, April 10th. Finally, BTIG Research restated a “buy” rating and set a $38.00 price objective on shares of Cullinan Therapeutics in a research report on Tuesday, May 19th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Cullinan Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Read Our Latest Report on CGEM

Insider Transactions at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $14.62, for a total value of $116,960.00. Following the sale, the insider directly owned 166,844 shares in the company, valued at approximately $2,439,259.28. The trade was a 4.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 8.60% of the company’s stock.

Cullinan Therapeutics Company Profile

(Free Report)

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.